SCHEMBL3271808

SCHEMBL3271808

CC(=O)c1c(-c2cccc(C)n2)nn2ccccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MIF P14174 2/20 0.45
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
PDE5A O76074 1/20 0.45
ALDH1A1 P00352 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
TSHR P16473 1/20 0.45
PDE4A P27815 1/20 0.45
ADORA2A P29274 1/20 0.45
ADORA1 P30542 1/20 0.45
CYP2C19 P33261 1/20 0.45
BLM P54132 1/20 0.45
PDE4B Q07343 1/20 0.45
PDE4C Q08493 1/20 0.45
PDE4D Q08499 1/20 0.45
PDE3B Q13370 1/20 0.45
PDE3A Q14432 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4864274 0.90 MIF (0.45) MIFKMT2AMEN1PDE5AALDH1A1
SCHEMBL4865701 0.84 EGFR (0.55) MIFKMT2AMEN1PDE5AALDH1A1
SCHEMBL3277558 0.81 POLB (0.41) MIFKMT2AMEN1PDE5AALDH1A1
SCHEMBL13382196 0.81 BAZ2B (0.52) MIFKMT2AMEN1PDE5AALDH1A1
SCHEMBL27628762 0.79 MIF (0.42) MIFKMT2AMEN1PDE5AALDH1A1
SCHEMBL4868073 0.78 TGFBR1 (0.43) TGFBR1TGFBR2CCR1CCR8
SCHEMBL7665680 0.77 EGFR (0.61) MIFKMT2AMEN1PDE5AALDH1A1
SCHEMBL4868193 0.77 TGFBR1 (0.41) MIFKMT2AMEN1PDE5AALDH1A1
SCHEMBL4865571 0.77 BAZ2B (0.44) TGFBR1TGFBR2BAZ2BBAZ2A
SCHEMBL13105301 0.76 EGFR (0.48) MIFKMT2AMEN1PDE5AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691865-B2 Pyrazolopyridines and methods of making and using the same BIOGEN IDEC MA INC. (US) 2010-04-06 US disclosed
EP-1551398-A4 PYRAZOLOPYRIDINES AND METHODS OF MAKING AND USING THE SAME BIOGEN IDEC INC (US) 2006-06-07 EP disclosed
US-20060106033-A1 Pyrazolopyridines and methods of making and using the same BIOGEN IDEC MA INC. 2006-05-18 US disclosed
EP-1551398-A1 PYRAZOLOPYRIDINES AND METHODS OF MAKING AND USING THE SAME Biogen Idec MA Inc. (US) 2005-07-13 EP disclosed
WO-2004022054-A1 PYRAZOLOPYRIDINES AND METHODS OF MAKING AND USING THE SAME BIOGEN IDEC MA INC. (US) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106033-A1 Pyrazolopyridines and methods of making and using the same ALK, ACVR1, ACVRL1 MIF 1257/4885KMT2A 1246/4885MEN1 3789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.